Please assess the completion status of the following clinical trial:

Trial Title: Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients with atrial fibrillation or flutter~* Age 18-84 years~* Willingness to participate in the study and ability to sign informed consent.~Exclusion Criteria:~* Atrial fibrillation due to a reversible cause~* moderate or severe mitral stenosis~* conditions other than atrial fibrillation that require anticoagulation (e.g., a prosthetic heart valve)~* A need for aspirin at a dose of \>165 mg a day or for both aspirin and P2Y-inhibitor~* Serious bleeding event in the previous 6 months or a high risk of bleeding (eg, active peptic ulcer disease)~* a platelet count of \<100,000/mm3 or hemoglobin level of \<10 g/dL~* stroke within the previous 10 days~* documented hemorrhagic tendencies, or blood dyscrasias~* Renal insufficiency (serum creatinine level of 12.5 mg per deciliter or calculated creatinine clearance of \<50 ml per minute)~* Weight in excess of 325 pounds~* Resting hypotension (systolic blood pressure of \<90mmHg) or resting hypertension (systolic blood pressure of \>170mmHg or diastolic blood pressure of \>110 mmHg)~* History of active malignancy requiring concurrent chemotherapy~* Known allergy to iodinated contrast material~* pregnancy, women of childbearing potential unwilling to use adequate contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- apixaban (Type: ACTIVE_COMPARATOR): apixaban 5 mg or 2.5 mg po bid
- warfarin (Type: PLACEBO_COMPARATOR): warfarin with target INR of 2-3

Based on this trial design, predict the completion outcome and termination type (if applicable).